CS5008 / CStone Pharma - LARVOL DELTA

Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor payload for small cell lung cancer and neuroendocrine tumors (AACR 2026) - "DLL3 is a clinically validated target in SCLC, serving as the target of tarlatamab, a T-cell engager...A single treatment with 10 mg/kg CS5008 achieved significant tumor growth inhibition in all 5 tested SCLC CDX models with different expression level of DLL3 and SSTR2 assessed by FACS, indicating the designated character of CS5005 to overcome the heterogeneity of SCLC... CS5008 demonstrated potent antitumor activity against SCLC by dual targeting of SSTR2 and DLL3, effectively addressing heterogeneity. Its favorable preclinical safety and robust PK support further clinical development. An IND application is expected by the end of 2026."

ADC • Bispecific • Preclinical • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • SSTR2

CS5008 - SSTR2/DLL3 Bispecific ADC (PRNewswire) - "CStone presented preclinical data...at AACR 2026....In SCLC CDX models, CS5008 demonstrated potent and broad-spectrum anti-tumor effects. A single dose induced tumor regression in various tumor models with different antigen expression levels. Notably, CS5008 outperformed DLL3-CSL20-Exa in the H446 (DLL3 negative SCLC) CDX model, indicating its potential to overcome tumor heterogeneity....CStone plans to initiate the IND application for CS5008 in the second half of 2026."

IND • Preclinical • Lung Neuroendocrine Carcinoma • Small Cell Lung Cancer

AACR 2026 Preview: CStone to Present Preclinical Data for Three Proprietary Pipeline Assets (CStone Pharma Press Release)

Preclinical • Neuroendocrine Tumor • Small Cell Lung Cancer